As the United States begins the 2025 COVID-19 booster campaign, public interest in alternative treatments like ivermectin has resurfaced. With limited booster access, debates surrounding prescription rules, insurance coverage, and social media-fueled discussions are intensifying. This article explores ivermectin's potential role, challenges, and public perception during the current booster...